Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00980005 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,116
- Enrollment target
NCT00980005 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,116 participants.
The verdict
NCT00980005, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,116 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK1557482A.
Interventions
- BIOLOGICAL Fluzone®
- BIOLOGICAL GSK investigational vaccine GSK1557482A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,116 participants |
| Start Date | 2009-10-13 |
| Est. Completion | 2010-06-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00980005
The ClinicalTrials.gov registry entry for NCT00980005 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluzone® is the first listed.
NCT00980005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00980005 about?
NCT00980005 is a clinical study titled "Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children". The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK1557482A.
What is the current status of trial NCT00980005?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,116 participants. The study started on 2009-10-13. Estimated completion is 2010-06-17.
What interventions are being tested in trial NCT00980005?
The interventions under investigation include: Fluzone® (BIOLOGICAL), GSK investigational vaccine GSK1557482A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00980005?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.